CXCR2 and influenza: We demonstrated that attenuation of neutrophil recruitment to the lungs by therapeutic treatment with the CXCR2 antagonist SB-332235Z together with OSV improved outcomes in a model of severe influenza infection, with no evidence of worsening outcome.